Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies (Nasdaq: TSHA) granted inducement equity to four new employees on April 1, 2026.

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) granted inducement equity to four new employees on April 1, 2026.

The Compensation Committee awarded 300,000 RSUs (vest in four equal annual installments) and an option for 92,400 shares with a $4.31 exercise price, a 10-year term, and four-year vesting.

Key Figures

Stock option exercise price: $4.31 Inducement RSUs granted: 300,000 shares Stock options granted: 92,400 shares +5 more

Stock option exercise price

$4.31

Exercise price equals closing price on grant date, April 1, 2026

Inducement RSUs granted

300,000 shares

Aggregate RSUs granted to four new employees under 2023 Inducement Plan

Stock options granted

92,400 shares

Option to purchase common stock granted to new employees

Number of new employees

4 employees

Recipients of inducement RSUs and stock option

RSU vesting schedule

4 annual installments

Vests in four equal annual installments from first anniversary

Option term

10 years

Contractual life of the stock option grant

Initial option vesting

25% at 1 year

First tranche vests on first anniversary of vesting commencement date

Remaining option vesting

75% over 36 months

Vests in equal monthly installments over subsequent 36 months

Historical Context

5 past events · Latest: Mar 19

5 events

1. Mar 19

   Earnings and update

   24h Move

   +2.5%

   Full-year 2025 results and Rett syndrome program progress with cash runway.

2. Mar 12

   Earnings date set

   24h Move

   +2.1%

   Announcement of date and webcast for full-year 2025 results call.

3. Mar 06

   Inducement grants

   24h Move

   +1.8%

   RSU and option inducement awards for two new employees under 2023 plan.

4. Feb 06

   Inducement RSUs

   24h Move

   +4.5%

   349,000 inducement RSUs granted to three new employees, time-based vesting.

5. Jan 06

   Clinical progress

   24h Move

   +7.6%

   TSHA-102 pivotal Rett trial progress and FDA alignment on broad label strategy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, rsus, stock option, exercise price, +3 more

7 terms

restricted stock units financial

"granted four new employees, in the aggregate, restricted stock units (RSUs) representing"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"restricted stock units (RSUs) representing 300,000 shares of the Company’s common stock"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

stock option financial

"and an option to purchase 92,400 shares of the Company's common stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The stock option has an exercise price of $4.31 which is equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The RSUs will vest in four equal annual installments beginning on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS, April 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 300,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through each such vesting date. The stock option has an exercise price of $4.31 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity did Taysha (TSHA) grant on April 1, 2026 to new employees?

Taysha granted 300,000 RSUs and an option for 92,400 shares to four new employees. According to the company, the awards were made as inducements under Nasdaq Listing Rule 5635(c)(4) in connection with employment.

How do the 300,000 RSUs granted by TSHA vest and when do they start?

The RSUs vest in four equal annual installments, beginning on the first anniversary of the vesting commencement date. According to the company, vesting is contingent on each employee's continued service through each vesting date.

What are the terms of the TSHA stock option granted April 1, 2026?

The option covers 92,400 shares, has a $4.31 exercise price, a 10-year term, and four-year vesting. According to the company, 25% vests after one year, then monthly over the remaining 36 months, subject to continued service.

Why did Taysha use an inducement grant under Nasdaq Rule 5635(c)(4) for the April 1, 2026 awards?

The awards were made as inducement grants to recruit new employees under Nasdaq Listing Rule 5635(c)(4). According to the company, the grants were material to the individuals entering employment with Taysha.

Does the April 1, 2026 TSHA option use the market price and how is it set?

Yes, the option exercise price is $4.31, equal to TSHA's closing stock price on the grant date. According to the company, the exercise price was set to match the closing price on April 1, 2026.